Lipid-lowering treatments and cardiovascular prevention in diabetic subjects: news and perspectives
Résumé
The atherosclerotic cardiovascular disease is the leading cau of death in diabetes. The treatment of the dyslipidemias and especially the exce of LDL-cholesterol (LDL-C) which is a major cardiovascul, risk factor allows the primary and the secondary preventic of cardiovascular events in diabetes. A new French consensus and guidelines from the Frenc National Authority for Health (HAS) have set the framewo for the management of dyslipidemias. Statins represent the first-line treatment of the excess of LDL The statin-fenofibrate association can be used in high ar very high cardiovascular risk patients with LDL-C at targ but with a residual atherogenic dyslipidemia. PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) inhibitc are a new therapeutic class highly effective in the reduction LDL-C whose launch on the market is still pending in Franc